Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243797 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
A Phase 3 study of Multiple Myeloma, sponsored by European Myeloma Network B.V..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,594
- Enrollment target
- 20
- Study locations
NCT05243797 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by European Myeloma Network B.V.. The registered enrollment target is 1,594 participants, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (194% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05243797, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by European Myeloma Network B.V..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,594 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Lenalidomide
Study Locations (20)
California
- UCLA Medical Center - Los Angeles
- University of California-Davis Cancer Center - Sacramento
- University of California, San Diego (UCSD) Medical Center - San Diego
Colorado
- University of Colorado Hospital - Aurora
- Colorado Blood Cancer Institute - Denver
Florida
- Blood & Marrow Transplant Center, Florida Hospital Medical Group - Orlando
- Moffitt at Memorial Healthcare System - Tampa
Maryland
- Greenebaum Cancer Center UM of MD - Baltimore
- John Hopkins - Baltimore
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Mount Sinai Medical Center - 2 - New York
- Montefiore Medical Cente - The Bronx
Arizona
- Banner University Medical Center Tucson, University of Arizona - Phoenix
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,594 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2032-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243797
The ClinicalTrials.gov registry entry for NCT05243797 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (194% higher). The listed sponsor is European Myeloma Network B.V., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.
NCT05243797 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05243797 about?
NCT05243797 is a clinical study titled "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation". This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
What is the current status of trial NCT05243797?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,594 participants. The study started on 2022-09-08. Estimated completion is 2032-04.
What conditions does trial NCT05243797 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05243797?
The interventions under investigation include: Teclistamab (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT05243797?
This trial is sponsored by European Myeloma Network B.V., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05243797 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.